Clinical application of radiophotoluminescent glass dosimeter for dose verification of prostate HDR procedure.
High dose rate brachytherapy (HDR-BT) is one of the many modalities for prostate cancer treatment. Due to the nature of HDR-BT, in vivo dosimetry is feasible and can be used to verify consistent dose delivery. In order to validate a dose verification system for HDR-BT prostate cancer treatment, a radiophotoluminescent glass dosimeter (RPLGD) was used and the measurements were compared with those from a thermoluminescent dosimeter. The RPLGD shows many advantages in HDR-BT dose measurement, such as repeatability, stability, and small effective size. These advantages make the RPLGD a superior option for use as a dosimeter in HDR-BT. The results described here show that the difference between the measured dose and the treatment planned dose is less than 5%. A Monte Carlo simulation for the dose was performed using Monte Carlo N -particle to investigate position error. This study concludes that the RPLGD is a promising and reliable dosimeter for HDR-BT in vivo dosimetry with clinically acceptable accuracy.
Hsu
Shih-Ming
SM
Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan, Republic of China.
Yeh
Chien-Yi
CY
Yeh
Tien-Chi
TC
Hong
Ji-Hong
JH
Tipton
Annie Y H
AY
Chen
Wei-Li
WL
Sun
Shung-Shung
SS
Huang
David Y C
DY
D001918:Brachytherapy / Q000379:methods*; D004307:Dose-Response Relationship, Radiation; D004867:Equipment Design; D005898:Glass; D006801:Humans; D008297:Male; D009010:Monte Carlo Method; D019047:Phantoms, Imaging; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011829:Radiation Dosage; D011874:Radiometry / Q000379:methods; D011879:Radiotherapy Dosage; D015203:Reproducibility of Results; D013819:Thermoluminescent Dosimetry / Q000379:methods*; D014867:Water
D014867:Water